Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival

Abstract

Purpose MMP9 is a matricellular protein associated with extracellular matrix (ECM) remodelling, that promotes tumour progression, and modulates the activity of cell adhesion molecules and cytokines. This study aims to assess the prognostic value of MMP9 and its association with cytoskeletal modulators in early-stage invasive breast cancer (BC). Methods MMP9 expression was evaluated by immunohistochemistry using a well-characterised series of primary BC patients with long-term clinical follow-up. Association with clinicopathological factors, patient outcome and ECM remodelling BC-biomarkers were investigated. METABRIC dataset, BC-GenExMiner v4.0 and TCGA were used for the external validation of MMP9 expression. GSEA gene enrichment analyses were used to evaluate MMP9 associated pathways. Results MMP9 immunopositivity was observed in the stroma and cytoplasm of BC cells. Elevated MMP9 protein levels were associated with high tumour grade, high Nottingham Prognostic Index, and hormonal receptor negativity. Elevated MMP9 protein expression correlated significantly with cytokeratin 17 (Ck17), Epidermal Growth Factor Receptor (EGFR), proliferation (Ki67) biomarkers, cell surface adhesion receptor (CD44) and cell division control protein 42 (CDC42). Cytoplasmic MMP9 expression was an independent prognostic factor associated with shorter BC-specific survival. In the external validation cohorts, MMP9 expression was also associated with poor patients' outcome. Transcriptomic analysis confirmed a positive association between MMP9 and ECM remodelling biomarkers. GSEA analysis supports MMP9 association with ECM and cytoskeletal pathways. Conclusion This study provides evidence for the prognostic value of MMP9 in BC. Further functional studies to decipher the role of MMP9 and its association with cytoskeletal modulators in BC progression are warranted. Keywords MMP9 • Breast cancer • ECM remodelling • Prognosis Abbreviations BC Breast cancer BCSS BC-specific survival CI Confidence intervals DGE Differential gene expression ER Oestrogen HR Hazard ratio HER2 Human epidermal growth factor receptor 2 METABRIC Molecular taxonomy of breast cancer international consortium NPI Nottingham Prognostic Index PR Progesterone

Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis

“…Then, 27 studies were excluded as they detected MMP2/MMP9 expression in serum ( n = 17) or cytosol tumor extracts ( n = 1) or in stromal cells ( n = 1), investigated mRNA expression ( n = 4), duplicated with others ( n = 4). Finally, a total of 41 studies comprising 6517 patients with primary breast cancers [ 16 – 23 , 27 – 59 ] were included in our meta-analysis (Fig. 1 ).…”

CD2 Is a Novel Immune-Related Prognostic Biomarker of Invasive Breast Carcinoma That Modulates the Tumor Microenvironment

“…Spearman's correlation analysis was used to determine the correlation between CD2 expression and tumor mutation burden (TMB) using the "ggstatsplot" R package. External validation of the survival analysis was performed using the METABRIC data cohort using Breast Cancer Gene-Expression Miner v4.5 software (bc-GenExMiner v4.5; http://bcgenex.centregauducheau.fr) (19). The Kruskal-Wallis rank sum test was used to assess the associations between CD2 expression and TMN staging using the "ggpubr" R package.…”

Chronic lung diseases are associated with gene expression programs favoring SARS-CoV-2 entry and severity

“…The tissue samples were obtained after informed consent and local ethics approval (South East Scotland SAHSC Bioresource-reference number 06/S1101/41; Brompton Node samples -reference number 15/SC/0101; Papworth Node Samples; non-diseased controls-reference number (Q)GM030404 and Nottingham BRC samples-reference number 08/H0407/1). IHC staining was performed using the Novocastra Novolink™ Polymer Detection Systems kit (Code: RE7280-K, Leica, Biosystems, Newcastle, UK) as previously described 79 . Heat-induced citrate antigen retrieval (pH 6.0) and pepsin antigen retrieval was performed for Rabbit monoclonal ACE2 (ab108252, EPR4435(2) Abcam, UK) and the anti-αvβ6 integrin antibody (6.2A1; Biogen, Cambridge, MA, USA), respectively.…”